Amgen's hyped Humira biosimilar fritters away its exclusivity advantage

In January, when Amgen launched the first biosimilar to compete with AbbVie’s Humira in the U.S., the company looked forward to six months of exclusivity in competing one-on-one against the immunology powerhouse.